← Back to Search

Behavioral Intervention

GLAm App for Cancer Survivors' HPV Vaccination

N/A

Recruiting

Led By Deanna Teoh, MD, MS

Research Sponsored by Masonic Cancer Center, University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Survivor of childhood cancer (defined as diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age.

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year post index clinic visit

Awards & highlights

Study Summary

This trial aims to boost HPV vaccination rates for cancer survivors aged between pediatric and young adult.

Who is the study for?

This trial is for pediatric, adolescent, and young adult cancer survivors aged 9-26 who are patients at specific clinics. It's also open to those treated for hematologic disorders with immunosuppression or HSCT. Participants must be at least 6 months post-treatment and either have not started or not completed the HPV vaccine series.Check my eligibility

What is being tested?

The study aims to increase HPV vaccination rates among young cancer survivors using a digital application called GLAm app. The focus is on starting and completing the three-dose HPV vaccine regimen in this vulnerable population.See study design

What are the potential side effects?

Since this trial involves the use of an app to encourage vaccination rather than testing a new medication, there are no direct side effects from the intervention itself. However, common side effects of HPV vaccines can include pain at injection site, headache, fever, nausea, and dizziness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was diagnosed with cancer before 26 and am now 18-26, or I care for someone who was and is now 9-17.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year post index clinic visit

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year post index clinic visit

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post index clinic visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Study enrollment

Secondary outcome measures

Cancer occurrences associated with vaccination status

Change in HPV and HPV vaccination knowledge pre- and post-intervention

Concordance between reported and documented vaccination against HPV

+6 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: GLAm AppExperimental Treatment1 Intervention

Participants will have access to Game based Learning Avatar navigated mobile (GLAm ) app and will receive the receive the quality improvement (QI) intervention plus the GLAm app.

Group II: Usual careActive Control1 Intervention

Participants in the control group will not receive the access to the GLAm app. They will receive the quality improvement (QI) intervention only.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor

272 Previous Clinical Trials

14,163 Total Patients Enrolled

Deanna Teoh, MD, MSPrincipal InvestigatorMasonic Cancer Center, University of Minnesota

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are the elderly able to participate in this investigation?

"The age range for this clinical trial is from 9 to 26 years old."

Answered by AI

Are new participants currently being enrolled in this investigation?

"Clinicaltrials.gov has indicated that, since its posting on July 24th 2023 and most recent update in December 4th of the same year, this clinical trial is actively seeking out patients to participate."

Answered by AI

What criteria makes a person an ideal candidate for this clinical trial?

"Eligibility for this clinical trial necessitates that participants have cancer and are between 9 and 26 years of age. A total of 490 patients will be recruited to take part in the study."

Answered by AI

How many individuals are expected to participate in this experiment?

"Affirmative. According to clinicaltrials.gov, the medical study is still searching for participants - it was first posted on July 24th 2023 and last updated on December 4th 2023. 490 individuals are being sought from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors

2023. "Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05665543.